Lantern Pharma Meets FDA to Advance AI-Driven Lung Cancer Trial | LTRN

Apr 20, 2026

Lantern Pharma (NASDAQ: LTRN) has scheduled a Type C meeting with the FDA to discuss protocol amendments for its ongoing Phase 2 HARMONIC trial evaluating LP-300 in non-small cell lung cancer. The proposed updates are based on emerging data showing a meaningful progression-free survival signal in patients with limited treatment options.

The company aims to refine the trial design to better target patients most likely to benefit, leveraging its AI-driven precision oncology platform to accelerate development and improve outcomes in a high-need population.

#LanternPharma
#LTRN
#Biotech
#LungCancer
#Oncology
#ClinicalTrials
#AI
#PrecisionMedicine
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#FDA
#JaneKing
#NewsOut